UNLABELLED: Chronic liver injury promotes hepatic inflammation, representing a prerequisite for organ fibrosis. We hypothesized a contribution of chemokine receptor CCR6 and its ligand, CCL20, which may regulate migration of T-helper (Th)17, regulatory, and gamma-delta (γδ) T cells. CCR6 and CCL20 expression was intrahepatically up-regulated in patients with chronic liver diseases (n = 50), compared to control liver (n = 5). Immunohistochemistry revealed the periportal accumulation of CCR6(+) mononuclear cells and CCL20 induction by hepatic parenchymal cells in liver disease patients. Similarly, in murine livers, CCR6 was expressed by macrophages, CD4 and γδ T-cells, and up-regulated in fibrosis, whereas primary hepatocytes induced CCL20 upon experimental injury. In two murine models of chronic liver injury (CCl4 and methionine-choline-deficient diet), Ccr6(-/-) mice developed more severe fibrosis with strongly enhanced hepatic immune cell infiltration, compared to wild-type (WT) mice. Although CCR6 did not affect hepatic Th-cell subtype composition, CCR6 was explicitly required by the subset of interleukin (IL)-17- and IL-22-expressing γδ T cells for accumulation in injured liver. The adoptive transfer of WT γδ, but not CD4 T cells, into Ccr6(-/-) mice reduced hepatic inflammation and fibrosis in chronic injury to WT level. The anti-inflammatory function of hepatic γδ T cells was independent of IL-17, as evidenced by transfer of Il-17(-/-) cells. Instead, hepatic γδ T cells colocalized with hepatic stellate cells (HSCs) in vivo and promoted apoptosis of primary murine HSCs in a cell-cell contact-dependent manner, involving Fas-ligand (CD95L). Consistent with γδ T-cell-induced HSC apoptosis, activated myofibroblasts were more frequent in fibrotic livers of Ccr6(-/-) than in WT mice. CONCLUSION: γδ T cells are recruited to the liver by CCR6 upon chronic injury and protect the liver from excessive inflammation and fibrosis by inhibiting HSCs.
UNLABELLED: Chronic liver injury promotes hepatic inflammation, representing a prerequisite for organ fibrosis. We hypothesized a contribution of chemokine receptor CCR6 and its ligand, CCL20, which may regulate migration of T-helper (Th)17, regulatory, and gamma-delta (γδ) T cells. CCR6 and CCL20 expression was intrahepatically up-regulated in patients with chronic liver diseases (n = 50), compared to control liver (n = 5). Immunohistochemistry revealed the periportal accumulation of CCR6(+) mononuclear cells and CCL20 induction by hepatic parenchymal cells in liver diseasepatients. Similarly, in murine livers, CCR6 was expressed by macrophages, CD4 and γδ T-cells, and up-regulated in fibrosis, whereas primary hepatocytes induced CCL20 upon experimental injury. In two murine models of chronic liver injury (CCl4 and methionine-choline-deficient diet), Ccr6(-/-) mice developed more severe fibrosis with strongly enhanced hepatic immune cell infiltration, compared to wild-type (WT) mice. Although CCR6 did not affect hepatic Th-cell subtype composition, CCR6 was explicitly required by the subset of interleukin (IL)-17- and IL-22-expressing γδ T cells for accumulation in injured liver. The adoptive transfer of WT γδ, but not CD4 T cells, into Ccr6(-/-) mice reduced hepatic inflammation and fibrosis in chronic injury to WT level. The anti-inflammatory function of hepatic γδ T cells was independent of IL-17, as evidenced by transfer of Il-17(-/-) cells. Instead, hepatic γδ T cells colocalized with hepatic stellate cells (HSCs) in vivo and promoted apoptosis of primary murine HSCs in a cell-cell contact-dependent manner, involving Fas-ligand (CD95L). Consistent with γδ T-cell-induced HSC apoptosis, activated myofibroblasts were more frequent in fibrotic livers of Ccr6(-/-) than in WT mice. CONCLUSION: γδ T cells are recruited to the liver by CCR6 upon chronic injury and protect the liver from excessive inflammation and fibrosis by inhibiting HSCs.
Authors: Tatiana I Novobrantseva; Gerard R Majeau; Aldo Amatucci; Sophia Kogan; Ian Brenner; Stefano Casola; Mark J Shlomchik; Victor Koteliansky; Paula S Hochman; Alexander Ibraghimov Journal: J Clin Invest Date: 2005-11 Impact factor: 14.808
Authors: Andrea Bonacchi; Ilaria Petrai; Raffaella M S Defranco; Elena Lazzeri; Francesco Annunziato; Eva Efsen; Lorenzo Cosmi; Paola Romagnani; Stefano Milani; Paola Failli; Giacomo Batignani; Francesco Liotta; Giacomo Laffi; Massimo Pinzani; Paolo Gentilini; Fabio Marra Journal: Gastroenterology Date: 2003-10 Impact factor: 22.682
Authors: Lisa A Mielke; Sarah A Jones; Mathilde Raverdeau; Rowan Higgs; Anna Stefanska; Joanna R Groom; Alicja Misiak; Lara S Dungan; Caroline E Sutton; Gundula Streubel; Adrian P Bracken; Kingston H G Mills Journal: J Exp Med Date: 2013-05-20 Impact factor: 14.307
Authors: Silvia Affò; Oriol Morales-Ibanez; Daniel Rodrigo-Torres; José Altamirano; Delia Blaya; Dianne H Dapito; Cristina Millán; Mar Coll; Jorge M Caviglia; Vicente Arroyo; Juan Caballería; Robert F Schwabe; Pere Ginès; Ramón Bataller; Pau Sancho-Bru Journal: Gut Date: 2014-01-10 Impact factor: 23.059
Authors: Lena Seifert; Michael Deutsch; Sara Alothman; Dalia Alqunaibit; Gregor Werba; Mridul Pansari; Matthew Pergamo; Atsuo Ochi; Alejandro Torres-Hernandez; Elliot Levie; Daniel Tippens; Stephanie H Greco; Shaun Tiwari; Nancy Ngoc Giao Ly; Andrew Eisenthal; Eliza van Heerden; Antonina Avanzi; Rocky Barilla; Constantinos P Zambirinis; Mauricio Rendon; Donnele Daley; H Leon Pachter; Cristina Hajdu; George Miller Journal: Cell Rep Date: 2015-11-19 Impact factor: 9.423